戻る
Medicenna Therapeutics Corp (MDNAF)価格
MDNAF 株価推移チャート
MDNAF 収入
Medicenna Therapeutics Corp
$0.68
-1.73%
$-0.01
終値： Jan 23, 16:00:00 GMT-5
$0.68
0%
$0
アフターマーケット：Jan 23, 20:00:00 GMT-5
主要データ
前終値
$0.7
始値
$0.7211
当日レンジ
$0.6751 - $0.7211
52週レンジ
$0.573 - $1.43
取引高
--
平均取引高
134.3K
1株当たり利益(TTM)
-0.12
配当利回り
--
時価総額
$57.3M
Medicenna Therapeutics Corp.とは何ですか？
Medicenna Therapeutics Corp. is a clinical stage immuno-oncology company. The company is headquartered in Toronto, Ontario and currently employs 18 full-time employees. The company went IPO on 2015-07-13. Its long-acting IL-2 Superkine, MDNA11, is a IL-2 with superior affinity toward CD122 (IL-2 receptor beta) and no CD25 (IL-2 receptor alpha) binding, thereby preferentially stimulating cancer-killing effector T cells and NK cells. Its IL-4 Empowered Superkine, bizaxofusp, has been studied in five clinical trials, including a Phase IIb trial for recurrent glioblastoma (GBM). Its early-stage high-affinity IL-2B biased IL-2/IL-15 Super-antagonists, from its MDNA209 platform, are being evaluated as potential therapies for autoimmune and graft-versus host diseases. Its early-stage BiSKITs (Bifunctional SuperKine ImmunoTherapies) and the T-MASK (Targeted Metalloprotease Activated SuperKine) programs are designed to enhance the ability of Superkines to treat immunologically cold tumors.